Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
149 hedge funds and large institutions have $1.53B invested in Revance Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 50 reducing their positions, and 17 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 50
6% more call options, than puts
Call options by funds: $9.56M | Put options by funds: $9.03M
3% more capital invested
Capital invested by funds: $1.49B → $1.53B (+$44.4M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1% less funds holding
Funds holding: 151 → 149 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$17M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$14.6M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$12.2M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$10.6M |
| 5 |
BlackRock
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$16.1M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$13.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$12M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.06M |
| 5 |
OCM
Osterweis Capital Management
San Francisco,
California
|
-$4.96M |
RVNC Hedge Fund Activity: Q1 2021 in Review
149 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2021, worth a combined $1.53B — up 3% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RVNC and 16 opened new positions — a net loss of 1 holder — while 50 trimmed existing stakes and 58 added.
The largest buyer was HighTower Advisors, adding an estimated $17M. The largest seller was Essex Woodlands Management, cutting an estimated $16.1M.
- 149 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2021, down from 151 in Q4 2020.
- Funds reported $1.53B of Revance Therapeutics, Inc. stock for Q1 2021, up 3% quarter-over-quarter.
- 16 funds opened new Revance Therapeutics, Inc. positions in Q1 2021 and 17 closed out, a net change of -1 holder.
- The largest Revance Therapeutics, Inc. buyer in Q1 2021 was HighTower Advisors, an estimated $17M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2021 was Essex Woodlands Management, an estimated $16.1M sold.
Based on aggregated 13F filings for Q1 2021.